Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Iterum Therapeutics plc (ITRM)

1.21   0.02 (1.68%) 01-27 15:59
Open: 1.17 Pre. Close: 1.19
High: 1.22 Low: 1.15
Volume: 47,043 Market Cap: 15(M)

Technical analysis

as of: 2023-01-27 4:45:37 PM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 1.51     One year: 1.77
Support: Support1: 0.86    Support2: 0.6
Resistance: Resistance1: 1.29    Resistance2: 1.51
Pivot: 1.15
Moving Average: MA(5): 1.19     MA(20): 1.09
MA(100): 1.46     MA(250): 3.08
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 76.5     %D(3): 75.9
RSI: RSI(14): 57.8
52-week: High: 7.05  Low: 0.19
Average Vol(K): 3-Month: 372 (K)  10-Days: 70 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ITRM ] has closed below upper band by 36.3%. Bollinger Bands are 32.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.22 - 1.23 1.23 - 1.23
Low: 1.14 - 1.14 1.14 - 1.15
Close: 1.2 - 1.21 1.21 - 1.22

Company Description

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Headline News

Wed, 11 Jan 2023
Do Traders Think Iterum Therapeutics PLC (ITRM) Can Keep Climbing Wednesday? - InvestorsObserver

Wed, 11 Jan 2023
Lipella, Inotiv top healthcare gainers; Tonix, Prenetics among losers - Seeking Alpha

Thu, 15 Dec 2022
Iterum Therapeutics PLC (ITRM) Stock Increases 15.38% This Week; Should You Buy? - InvestorsObserver

Thu, 15 Dec 2022
Iterum Therapeutics rises 21% on U.S. patent covering oral sulopenem - Seeking Alpha

Wed, 16 Nov 2022
Wings welcome ITRM as official IT partner and back-of-shirt sponsor - Welling United FC

Thu, 20 Oct 2022
Iterum Announces First Patient Dosed in REASSURE, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 12 (M)
Shares Float 12 (M)
% Held by Insiders 0.7 (%)
% Held by Institutions 2.8 (%)
Shares Short 140 (K)
Shares Short P.Month 217 (K)

Stock Financials

EPS 0.12
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.66
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -21.6
Return on Equity (ttm) -102.5
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.14
Qtrly Earnings Growth 0
Operating Cash Flow -17 (M)
Levered Free Cash Flow -15 (M)

Stock Valuations

PE Ratio 9.3
PEG Ratio 0
Price to Book value 0.45
Price to Sales 0
Price to Cash Flow -0.89

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.